
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is projected to experience a compound annual revenue growth rate of 5.4% in its Lab Products and Services segment over the next three years, despite a decline from the previous five-year period's growth of 16.9%. The company's expansion includes a significant acquisition, Clario, valued at $8.9 billion, which is expected to enhance its competitive position in the contract research organization (CRO) market, benefiting from increased outsourcing trends in biopharma clinical trials. Additionally, adjusted earnings per share (EPS) are anticipated to rise at an 8.5% compound annual rate over the next four years, indicating robust financial health and operational performance.
Bears say
Thermo Fisher Scientific experienced a significant decline in key financial metrics from 2021 to 2024, with adjusted EBIT margins falling by approximately 830 basis points to 22.6% and adjusted gross margins decreasing by 940 basis points to 42.2%, both metrics indicating worsening profitability. Additionally, the company's gross margins are now notably below levels achieved in 2019, further emphasizing a downward trend in financial performance. Compounding these concerns, funding for biotechnology projects in 2025 has started off slowly, with a 45% year-over-year decline in capital raised during the year's first half, suggesting potential challenges in future revenue growth.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares